Ignazio Barbagallo

1. Introduction Hypertension, also known as high blood pressure (BP), is an important public health issue affecting approximately 1 billion people globally [1]. Hypertension is a leading risk factor for cardiovascular disease (CVD) and a major contributor to the burden of disease worldwide [2]. Elevated BP has been estimated to be responsible for approximately 7.5 million deaths and 127.5 million disability-adjusted life years each year [3].

Abstract : Although mangiferin (MGN) is a natural antioxidant that could be a good candidate for the treatment of ocular diseases, its use in ophthalmology is strongly compromised due to its high lipophilicity. Its encapsulation in nanostructured lipid carriers (NLC) seems to be an interesting strategy for improving its ocular bioavailability. As reported in our previous work, MGN–NLC showed high ocular compatibility and fulfilled the nanotechnological requirements needed for ocular delivery.

Abstract Background In preparation for the 2021 revision of the European Union Tobacco Products Directive, the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) has posted its Preliminary Opinion on Electronic Cigarettes. They concluded that e-cigarettes only achieve a sub-optimal level of protection of human health.